ATE545708T1 - Krebsantigen mage-a9 und verwendungen davon - Google Patents

Krebsantigen mage-a9 und verwendungen davon

Info

Publication number
ATE545708T1
ATE545708T1 AT06817649T AT06817649T ATE545708T1 AT E545708 T1 ATE545708 T1 AT E545708T1 AT 06817649 T AT06817649 T AT 06817649T AT 06817649 T AT06817649 T AT 06817649T AT E545708 T1 ATE545708 T1 AT E545708T1
Authority
AT
Austria
Prior art keywords
mage
diagnosis
administering
prevention
accomplished
Prior art date
Application number
AT06817649T
Other languages
English (en)
Inventor
Alain Bergeron
Valerie Picard
Helene Larue
Yves Fradet
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Application granted granted Critical
Publication of ATE545708T1 publication Critical patent/ATE545708T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
AT06817649T 2005-11-14 2006-11-14 Krebsantigen mage-a9 und verwendungen davon ATE545708T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73585905P 2005-11-14 2005-11-14
PCT/CA2006/001853 WO2007053956A1 (en) 2005-11-14 2006-11-14 Cancer antigen mage-a9 and uses thereof

Publications (1)

Publication Number Publication Date
ATE545708T1 true ATE545708T1 (de) 2012-03-15

Family

ID=38022943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06817649T ATE545708T1 (de) 2005-11-14 2006-11-14 Krebsantigen mage-a9 und verwendungen davon

Country Status (5)

Country Link
US (1) US20090028888A1 (de)
EP (2) EP2305827A1 (de)
AT (1) ATE545708T1 (de)
CA (1) CA2630023A1 (de)
WO (1) WO2007053956A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3234193B1 (de) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molekulare biomarker für krebsimmuntherapie
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
CN105181966B (zh) * 2015-09-02 2017-08-11 南通大学附属医院 一种mage‑a9的用途
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
CR20200059A (es) 2017-07-07 2020-06-01 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US6333170B1 (en) * 1993-04-15 2001-12-25 National Jewish Center For Immunology And Respiratory Medicine Method and product for regulating cell responsiveness to external signals
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6287569B1 (en) * 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
CZ298364B6 (cs) * 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
JP2003512814A (ja) 1999-03-02 2003-04-08 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ＭＡＧＥ５、８、９および１１のｃＤＮＡのクローニングならびに癌の診断におけるそれらの使用
EP1339872A2 (de) * 2000-09-19 2003-09-03 Whitehead Institute For Biomedical Research Genetische marker für tumore
US20030165864A1 (en) * 2001-01-16 2003-09-04 Lasek Amy W. Genes regulated by DNA methylation in tumor cells
US20030013099A1 (en) * 2001-03-19 2003-01-16 Lasek Amy K. W. Genes regulated by DNA methylation in colon tumors
WO2002103028A2 (en) * 2001-05-30 2002-12-27 Biomedical Center In silico screening for phenotype-associated expressed sequences
MXPA04009554A (es) * 2002-04-01 2005-01-25 Euro Celtique Sa Construcciones epitopes que comrpenden antigeno presentando mecanismos de marcacion celular.

Also Published As

Publication number Publication date
US20090028888A1 (en) 2009-01-29
EP2305827A1 (de) 2011-04-06
EP1951891A4 (de) 2009-02-25
EP1951891B1 (de) 2012-02-15
CA2630023A1 (en) 2007-05-18
EP1951891A1 (de) 2008-08-06
WO2007053956A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
ATE545708T1 (de) Krebsantigen mage-a9 und verwendungen davon
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
WO2013033629A3 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
EA200702203A1 (ru) Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений
EA200800087A1 (ru) Генетические варианты гена tcf7l2 как диагностические маркеры риска возникновения сахарного диабета ii типа
TW200745556A (en) Biomarkers for liver fibrotic injury
EP2379577A4 (de) Zusammensetzungen und verfahren zur umprogrammierung von zellen ohne genetische modifikation
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
ATE461294T1 (de) Brustkrebsdiagnoseverfahren
MA30393B1 (fr) Procede de traitement, de diagnostic ou de detection du cancer
MX2007008984A (es) Marcadores de cancer y metodos de deteccion.
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
AU2006228990A8 (en) A method of diagnosis and treatment and agents useful for same
EP2083018A3 (de) Zusammensetzungen und Verfahren mit Bezug zu STOP-1
CN101748206B (zh) 小麦条锈菌与叶锈菌的复合pcr检测鉴定试剂盒
WO2007071829A3 (en) Methods and means related to diseases
WO2010036031A3 (en) Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
FI20022064A0 (fi) Nukleiinihappokoettimia, universaaleja alukkeita ja menetelmiä, joissa niitä käytetään
WO2007038762A3 (en) Penumbra nucleic acid molecules, proteins and uses thereof
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
WO2008077511A8 (en) Human polyomavirus and methods of diagnosis and treatment
CN101245367B (zh) 一种检测弓形虫的半巢式pcr方法
DE602004029477D1 (de) Methode zur detektion und beobachtung von krankheiten durch analyse von an den zellen gebundenen nukleinsäuren
EA200801822A1 (ru) Тест-система для диагностики рака предстательной железы и способ диагностики рака предстательной железы